Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Early increase of the synaptic blood marker β-synuclein in asymptomatic autosomal dominant Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association - 1 Apr 2025

Oeckl Patrick, Mayer Benjamin, Bateman Randall J, Day Gregory S, Fox Nick C, Huey Edward D, Ibanez Laura, Ikeuchi Takeshi, Jucker Mathias, Lee Jae-Hong, Levin Johannes, Llibre-Guerra Jorge J, Lopera Francisco, McDade Eric, Morris John C, Niimi Yoshiki, Roh Jee Hoon, Sánchez-Valle Raquel, Schofield Peter R, Otto Markus

Abstract excerpt

INTRODUCTION: β-synuclein is a promising blood marker to track synaptic degeneration in Alzheimer's disease (AD) but changes in preclinical AD are unclear. METHODS: We investigated serum β-synuclein in 69 cognitively unimpaired mutation non-carriers, 78 cognitively unimpaired AD mutation carriers (asymptomatic AD), and 31 symptomatic mutation carriers from the Dominantly Inherited Alzheimer Network. RESULTS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Alzheimer Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers

Share to Cognitive Dysfunction

Share to Longitudinal Studies

Share to Mutation

Share to Synapses

Source

Open in PubMed Open full text

Identifiers

PMID: 40207431
DOI: 10.1002/alz.70146
PMCID: PMC11982912

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early increase of the synaptic blood marker β-synuclein in asymptomatic autosomal dominant Alzheimer's disease.PMID 40207431Read ↗

α-synuclein as an emerging pathophysiological biomarker of Alzheimer’s diseaseSemantic proximity Read ↗

Associations between misfolded alpha‐synuclein aggregates and Alzheimer's disease pathology in vivoSemantic proximity Read ↗

Alpha-Synuclein Levels in Blood Plasma Decline with Healthy AgingSemantic proximity Read ↗

Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.Semantic proximity Read ↗

Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer’s diseaseSemantic proximity Read ↗

Cerebrospinal fluid and brain α-synuclein seed amplification in autopsy-confirmed Lewy body disease relates to the distribution of pathologySemantic proximity Read ↗

Blood neuro‐exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stageSemantic proximity Read ↗

Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseasesSemantic proximity Read ↗

Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson’s diseaseSemantic proximity Read ↗

Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional studySemantic proximity Read ↗

α-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden.Semantic proximity Read ↗

Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.